<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822441</url>
  </required_header>
  <id_info>
    <org_study_id>2019/CHU/14</org_study_id>
    <nct_id>NCT04822441</nct_id>
  </id_info>
  <brief_title>Prospective Study on the Risks of Dengue Fever for the Fetus.</brief_title>
  <acronym>ERiDenF</acronym>
  <official_title>Prospective Study on the Risks of Dengue Fever for the Fetus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dengue is the most common arbovirus worldwide (390 million people infected each year) and&#xD;
      belongs to the Flavivirus genus of the Flaviviridae family like Zika. Its expansion has been&#xD;
      rapid since the last decade with an increase in the number of cases of 400% and the first&#xD;
      cases of indigenous dengue described in Europe.&#xD;
&#xD;
      Current data on the consequences of dengue fever on the fetus are incomplete. The risk of&#xD;
      maternal-fetal transmission of dengue during the peripartum period has now been recorded in&#xD;
      numerous case reports and a few case series for patients who contracted dengue in the 12 days&#xD;
      preceding childbirth or at the time of delivery. However, the transmission of dengue is&#xD;
      highly variable depending on the studies ranging from 1.6 to 15% and the consequences for the&#xD;
      newborn are very variable ranging from simple thrombocytopenia to death in severe neonatal&#xD;
      dengue.&#xD;
&#xD;
      Regarding the risk of malformation, a few old cases of heart disease, hydrocephalus and&#xD;
      neural tube closure abnormalities have been described in the literature following exposure to&#xD;
      dengue fever during pregnancy. Since no malformative case has been described, however, to our&#xD;
      knowledge, no prospective study with specialized ultrasound monitoring has been performed for&#xD;
      pregnant women who contracted dengue during their pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study the teratogenic effects of the dengue virus on the fetus</measure>
    <time_frame>at childbirth</time_frame>
    <description>Rate of fetal anomalies such as infectious fetal disease or any other fetal anomaly detected during specialized antenatal ultrasound follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study the maternal-fetal transmission of dengue fever during pregnancy</measure>
    <time_frame>at childbirth</time_frame>
    <description>Amniotic fluid positive dengue PCR (Polymerase Chain Reaction) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the maternal-fetal transmission of dengue fever in the peri-partum</measure>
    <time_frame>at childbirth</time_frame>
    <description>Umbilical cord dengue positive and / or IgM (immunoglobulin M) positive PCR rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the materno-placental transmission of dengue fever during pregnancy and peri-partum</measure>
    <time_frame>at childbirth</time_frame>
    <description>Placental dengue positive PCR rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the consequences at the placental level of dengue, in terms of anatomopathological alterations</measure>
    <time_frame>at childbirth</time_frame>
    <description>Placental pathology abnormalities rate</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>Patients who contracted dengue fever before 34 weeks of amenorrhea</arm_group_label>
    <description>Patients who contracted biologically proven dengue fever during pregnancy before 34 weeks outside the peri-partum period (more than 12 days before childbirth)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who contracted dengue fever after 34 weeks of amenorrhea</arm_group_label>
    <description>Patients who contracted biologically proven dengue fever during pregnancy after 34 weeks outside the peri-partum period (more than 12 days before childbirth)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who have contracted dengue during the peripartum period</arm_group_label>
    <description>Patients who have contracted dengue during the peripartum period or who have a suspicion of dengue (in the 12 days preceding childbirth)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord</description>
    <arm_group_label>Patients who contracted dengue fever after 34 weeks of amenorrhea</arm_group_label>
    <arm_group_label>Patients who contracted dengue fever before 34 weeks of amenorrhea</arm_group_label>
    <arm_group_label>Patients who have contracted dengue during the peripartum period</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who contracted dengue fever during pregnancy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Major&#xD;
&#xD;
          -  Affiliated with social security&#xD;
&#xD;
          -  Symptomatic or pauci-symptomatic dengue&#xD;
&#xD;
          -  Biological confirmation of dengue fever by dengue positive PCR or IgM positive during&#xD;
             the current dengue episode&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Patient's refusal&#xD;
&#xD;
          -  Protected persons: person deprived of liberty by judicial or administrative decision,&#xD;
             minor, and person subject to a legal protection measure: guardianship or curators)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de la Réunion</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie AUZANNEAU</last_name>
      <phone>+262 (0) 262 35 99 49</phone>
      <email>lucie.auzanneau@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Marine LAFONT, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dengue fever ; pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

